Major Asian countries such as Japan, China, and India are witnessing a continuous growth in geriatric population. Owing to this, the prevalence of comorbidities associated with aging, such as osteoarthritis, diabetes, obesity, and osteoporosis is increasing in this region. This is a major factor driving the orthobiologics market in Asia. Moreover, over the past decade, there is a significant growth in the number of road accidents in Asia. This is resulting in an increase in demand for orthobiologics, as these products provide better bone healing as compared to mechanical bone healing procedures.
Download PDF Brochure@ http://www.micromarketmonitor.com/contact/7943449547-download_pdf_brochure.html
The viscosupplementation segment is the fastest-growing segment in the Asian orthobiologics market. Key industry players from the U.S. are expanding their product portfolio by launching new products and deliverables in the Asian market. In November 2014, Zimmer, Inc. launched the Puros Demineralized Bone Matrix (DBM) block and strip, a bone graft substitute which facilitates natural bone formation. This launch helped the company strengthen its biologics portfolio and provide easy-to-use allografts at a competitive price.
Speak to Analyst @ http://www.micromarketmonitor.com/contact/7943449547-speak_to_analyst.html
The key players in the Asian orthobiologics market are Biomet, Inc. (U.S.), Medtronic, Plc. (U.S.), Integra Life Sciences Corporation (U.S.), Stryker Corporation (U.S.), Zimmer, Inc. (U.S.), DePuy Synthes (U.S.), Tornier, Inc. (Netherlands), Nuvasive, Inc. (U.S.), Exactech, Inc. (U.S.), Globus Medical, Inc. (U.S.), and Wright Medical Technology, Inc. (U.S.).
